O	0	3	The	The	DT	B-NP
O	4	10	Kaposi	Kaposi	NNP	I-NP
O	10	11	'	'	POS	B-NP
O	11	12	s	s	NN	I-NP
O	13	20	sarcoma	sarcoma	NN	I-NP
O	20	21	-	-	HYPH	B-VP
O	21	31	associated	associate	VBN	B-NP
O	32	43	herpesvirus	herpesvirus	NN	I-NP
O	44	45	G	G	NN	I-NP
O	46	53	protein	protein	NN	I-NP
O	53	54	-	-	HYPH	B-NP
O	54	61	coupled	couple	VBN	I-NP
O	62	70	receptor	receptor	NN	I-NP
O	71	73	as	as	IN	B-PP
O	74	75	a	a	DT	B-NP
O	76	87	therapeutic	therapeutic	JJ	I-NP
O	88	94	target	target	NN	I-NP
O	95	98	for	for	IN	B-PP
O	99	102	the	the	DT	B-NP
O	103	112	treatment	treatment	NN	I-NP
O	113	115	of	of	IN	B-PP
B-Cancer	116	122	Kaposi	Kaposi	NNP	B-NP
I-Cancer	122	123	'	'	POS	B-NP
I-Cancer	123	124	s	s	JJ	I-NP
I-Cancer	125	132	sarcoma	sarcoma	NN	I-NP
O	132	133	.	.	.	O

O	135	138	The	The	DT	B-NP
O	139	145	Kaposi	Kaposi	NNP	I-NP
O	145	146	'	'	POS	B-NP
O	146	147	s	s	NN	I-NP
O	148	155	sarcoma	sarcoma	NN	I-NP
O	155	156	-	-	HYPH	O
O	156	166	associated	associate	VBN	B-VP
O	167	178	herpesvirus	herpesvirus	NN	B-NP
O	179	180	(	(	(	O
O	180	184	KSHV	KSHV	NN	B-NP
O	184	185	)	)	)	O
O	186	193	encodes	encode	VBZ	B-VP
O	194	195	a	a	DT	B-NP
O	196	197	G	G	NN	I-NP
O	198	205	protein	protein	NN	I-NP
O	205	206	-	-	HYPH	O
O	206	213	coupled	couple	VBN	B-VP
O	214	222	receptor	receptor	NN	B-NP
O	223	224	(	(	(	O
O	224	229	vGPCR	vGPCR	NN	B-NP
O	229	230	)	)	)	O
O	231	235	that	that	WDT	B-NP
O	236	239	has	have	VBZ	B-VP
O	240	244	been	be	VBN	I-VP
O	245	255	implicated	implicate	VBN	I-VP
O	256	258	in	in	IN	B-PP
O	259	262	the	the	DT	B-NP
O	263	273	initiation	initiation	NN	I-NP
O	274	276	of	of	IN	B-PP
B-Cancer	277	283	Kaposi	Kaposi	NNP	B-NP
I-Cancer	283	284	'	'	POS	B-NP
I-Cancer	284	285	s	s	NN	I-NP
I-Cancer	286	293	sarcoma	sarcoma	NN	I-NP
O	293	294	,	,	,	O
O	295	306	identifying	identify	VBG	B-VP
O	307	312	vGPCR	vGPCR	NN	B-NP
O	313	315	as	as	IN	B-PP
O	316	318	an	an	DT	B-NP
O	319	329	attractive	attractive	JJ	I-NP
O	330	336	target	target	NN	I-NP
O	337	340	for	for	IN	B-PP
O	341	351	preventing	prevent	VBG	B-VP
B-Cancer	352	358	Kaposi	Kaposi	NNP	B-NP
I-Cancer	358	359	'	'	POS	B-NP
I-Cancer	359	360	s	s	JJ	I-NP
I-Cancer	361	368	sarcoma	sarcoma	NN	I-NP
O	368	369	.	.	.	O

O	370	377	However	However	RB	B-ADVP
O	377	378	,	,	,	O
O	379	381	as	as	IN	B-SBAR
O	382	386	only	only	RB	B-NP
O	387	388	a	a	DT	I-NP
O	389	397	fraction	fraction	NN	I-NP
O	398	400	of	of	IN	B-PP
B-Cell	401	406	cells	cell	NNS	B-NP
O	407	409	in	in	IN	B-PP
O	410	418	advanced	advance	VBN	B-NP
B-Cancer	419	425	Kaposi	Kaposi	NNP	I-NP
I-Cancer	425	426	'	'	POS	B-NP
I-Cancer	426	427	s	s	JJ	I-NP
I-Cancer	428	435	sarcoma	sarcoma	NN	I-NP
I-Cancer	436	443	lesions	lesion	NNS	I-NP
O	444	451	express	express	VBP	B-VP
O	452	457	vGPCR	vGPCR	NN	B-NP
O	457	458	,	,	,	O
O	459	461	it	it	PRP	B-NP
O	462	464	is	be	VBZ	B-VP
O	465	472	unclear	unclear	JJ	B-ADJP
O	473	480	whether	whether	IN	B-SBAR
O	481	485	this	this	DT	B-NP
O	486	492	unique	unique	JJ	I-NP
O	493	498	viral	viral	JJ	I-NP
O	499	507	oncogene	oncogene	NN	I-NP
O	508	519	contributes	contribute	VBZ	B-VP
O	520	522	to	to	TO	B-PP
B-Cancer	523	529	Kaposi	Kaposi	NNP	B-NP
I-Cancer	529	530	'	'	POS	B-NP
I-Cancer	530	531	s	s	JJ	I-NP
I-Cancer	532	539	sarcoma	sarcoma	NN	I-NP
O	540	551	progression	progression	NN	I-NP
O	551	552	.	.	.	O

O	553	555	We	We	PRP	B-NP
O	556	565	therefore	therefore	RB	B-ADVP
O	566	569	set	set	VBD	B-VP
O	570	573	out	out	RP	B-PRT
O	574	576	to	to	TO	B-VP
O	577	586	determine	determine	VB	I-VP
O	587	594	whether	whether	IN	B-SBAR
O	595	598	the	the	DT	B-NP
O	599	602	few	few	JJ	I-NP
B-Cell	603	608	cells	cell	NNS	I-NP
O	609	613	that	that	WDT	B-NP
O	614	621	express	express	VBP	B-VP
O	622	627	vGPCR	vGPCR	NN	B-NP
O	628	630	in	in	IN	B-PP
O	631	642	established	established	JJ	B-NP
B-Cancer	643	649	tumors	tumor	NNS	I-NP
O	650	659	represent	represent	VBP	B-VP
O	660	662	an	an	DT	B-NP
O	663	674	appropriate	appropriate	JJ	I-NP
O	675	686	therapeutic	therapeutic	JJ	I-NP
O	687	693	target	target	NN	I-NP
O	694	697	for	for	IN	B-PP
O	698	701	the	the	DT	B-NP
O	702	711	treatment	treatment	NN	I-NP
O	712	714	of	of	IN	B-PP
O	715	723	patients	patient	NNS	B-NP
O	724	728	with	with	IN	B-PP
O	729	740	preexisting	preexist	VBG	B-VP
B-Cancer	741	747	Kaposi	Kaposi	NNP	B-NP
I-Cancer	747	748	'	'	POS	B-NP
I-Cancer	748	749	s	s	JJ	I-NP
I-Cancer	750	757	sarcoma	sarcoma	NN	I-NP
O	757	758	.	.	.	O

O	759	761	To	To	TO	B-PP
O	762	766	this	this	DT	B-NP
O	767	770	end	end	NN	I-NP
O	770	771	,	,	,	O
O	772	774	we	we	PRP	B-NP
O	775	784	generated	generate	VBD	B-VP
B-Cell	785	796	endothelial	endothelial	JJ	B-NP
I-Cell	797	801	cell	cell	NN	I-NP
I-Cell	802	807	lines	line	NNS	I-NP
O	808	814	stably	stably	RB	B-VP
O	815	825	expressing	express	VBG	I-VP
O	826	831	vGPCR	vGPCR	NN	B-NP
O	832	834	or	or	CC	O
O	835	838	key	key	JJ	B-NP
O	839	843	KSHV	KSHV	NN	I-NP
O	844	852	latently	latently	RB	B-NP
O	853	862	expressed	express	VBN	I-NP
O	863	871	proteins	protein	NNS	I-NP
O	872	873	(	(	(	O
O	873	880	vCyclin	vCyclin	NN	B-NP
O	880	881	,	,	,	O
O	882	887	vFlip	vFlip	NN	B-NP
O	887	888	,	,	,	O
O	889	892	and	and	CC	O
O	893	898	LANA1	LANA1	NN	B-NP
O	898	899	)	)	)	O
O	899	900	.	.	.	O

O	901	904	The	The	DT	B-NP
B-Cell	905	916	endothelial	endothelial	JJ	I-NP
I-Cell	917	921	cell	cell	NN	I-NP
I-Cell	922	926	line	line	NN	I-NP
O	927	937	expressing	express	VBG	B-VP
O	938	943	vGPCR	vGPCR	NN	B-NP
O	944	947	was	be	VBD	B-VP
O	948	956	rendered	render	VBN	I-VP
O	957	966	sensitive	sensitive	JJ	B-ADJP
O	967	969	to	to	TO	B-PP
O	970	979	treatment	treatment	NN	B-NP
O	980	984	with	with	IN	B-PP
O	985	988	the	the	DT	B-NP
O	989	999	nucleoside	nucleoside	NN	I-NP
O	1000	1008	analogue	analogue	NN	I-NP
O	1009	1020	ganciclovir	ganciclovir	NN	I-NP
O	1021	1023	by	by	IN	B-PP
O	1024	1029	using	use	VBG	B-VP
O	1030	1031	a	a	DT	B-NP
O	1032	1043	bicistronic	bicistronic	JJ	I-NP
O	1044	1053	construct	construct	NN	I-NP
O	1054	1066	coexpressing	coexpresse	VBG	B-VP
O	1067	1070	the	the	DT	B-NP
O	1071	1077	herpes	herpes	NN	I-NP
O	1078	1085	simplex	simplex	NN	I-NP
O	1086	1091	virus	virus	NN	I-NP
O	1092	1093	1	1	CD	I-NP
O	1094	1103	thymidine	thymidine	NN	I-NP
O	1104	1110	kinase	kinase	NN	I-NP
O	1110	1111	.	.	.	O

O	1112	1113	S	S	NN	B-NP
O	1113	1114	.	.	.	I-NP
O	1114	1115	c	c	NN	I-NP
O	1115	1116	.	.	.	I-NP
O	1117	1126	injection	injection	NN	I-NP
O	1127	1131	into	into	IN	B-PP
O	1132	1136	nude	nude	JJ	B-NP
O	1137	1141	mice	mouse	NNS	I-NP
O	1142	1146	with	with	IN	B-PP
B-Cell	1147	1152	mixed	mixed	JJ	B-NP
I-Cell	1152	1153	-	-	HYPH	I-NP
I-Cell	1153	1157	cell	cell	NN	I-NP
I-Cell	1158	1169	populations	population	NNS	I-NP
O	1170	1176	formed	form	VBD	B-VP
B-Cancer	1177	1183	tumors	tumor	NNS	B-NP
O	1184	1188	that	that	WDT	B-NP
O	1189	1200	approximate	approximate	VBP	B-VP
O	1201	1204	the	the	DT	B-NP
O	1205	1210	ratio	ratio	NN	I-NP
O	1211	1213	of	of	IN	B-PP
O	1214	1219	vGPCR	vGPCR	NN	B-NP
O	1219	1220	-	-	HYPH	O
O	1220	1230	expressing	express	VBG	B-VP
O	1231	1234	and	and	CC	O
O	1235	1239	KSHV	KSHV	NN	B-NP
O	1240	1246	latent	latent	JJ	I-NP
O	1247	1251	gene	gene	NN	I-NP
O	1251	1252	-	-	HYPH	O
O	1252	1262	expressing	express	VBG	B-VP
B-Cell	1263	1268	cells	cell	NNS	B-NP
O	1268	1269	.	.	.	O

O	1270	1275	These	These	DT	B-NP
O	1276	1280	mice	mouse	NNS	I-NP
O	1281	1285	were	be	VBD	B-VP
O	1286	1290	then	then	RB	I-VP
O	1291	1298	treated	treat	VBN	I-VP
O	1299	1303	with	with	IN	B-PP
O	1304	1315	ganciclovir	ganciclovir	NN	B-NP
O	1316	1318	to	to	TO	B-VP
O	1319	1331	specifically	specifically	RB	I-VP
O	1332	1338	target	target	VB	I-VP
O	1339	1343	only	only	RB	B-ADVP
O	1344	1347	the	the	DT	B-NP
O	1348	1353	vGPCR	vGPCR	NN	I-NP
O	1353	1354	-	-	HYPH	O
O	1354	1364	expressing	express	VBG	B-VP
B-Cell	1365	1370	cells	cell	NNS	B-NP
O	1370	1371	.	.	.	O

O	1372	1384	Surprisingly	Surprisingly	RB	B-ADVP
O	1384	1385	,	,	,	O
O	1386	1393	despite	despite	IN	B-PP
O	1394	1397	the	the	DT	B-NP
O	1398	1408	expression	expression	NN	I-NP
O	1409	1411	of	of	IN	B-PP
O	1412	1416	KSHV	KSHV	NN	B-NP
O	1417	1423	latent	latent	JJ	I-NP
O	1424	1429	genes	gene	NNS	I-NP
O	1430	1432	in	in	IN	B-PP
O	1433	1436	the	the	DT	B-NP
O	1437	1441	vast	vast	JJ	I-NP
O	1442	1450	majority	majority	NN	I-NP
O	1451	1453	of	of	IN	B-PP
B-Cell	1454	1459	tumor	tumor	NN	B-NP
I-Cell	1460	1465	cells	cell	NNS	I-NP
O	1465	1466	,	,	,	O
O	1467	1479	specifically	specifically	RB	B-VP
O	1480	1489	targeting	target	VBG	I-VP
O	1490	1494	only	only	RB	B-NP
O	1495	1498	the	the	DT	I-NP
O	1499	1502	few	few	JJ	I-NP
O	1503	1508	vGPCR	vGPCR	NN	I-NP
O	1508	1509	-	-	HYPH	O
O	1509	1519	expressing	express	VBG	B-VP
B-Cell	1520	1525	cells	cell	NNS	B-NP
O	1526	1528	in	in	IN	B-PP
O	1529	1540	established	established	JJ	B-NP
B-Cancer	1541	1547	tumors	tumor	NNS	I-NP
O	1548	1556	resulted	result	VBD	B-VP
O	1557	1559	in	in	IN	B-PP
B-Cancer	1560	1565	tumor	tumor	NN	B-NP
O	1566	1576	regression	regression	NN	I-NP
O	1576	1577	.	.	.	O

O	1578	1586	Moreover	Moreover	RB	B-ADVP
O	1586	1587	,	,	,	O
O	1588	1590	we	we	PRP	B-NP
O	1591	1599	observed	observe	VBD	B-VP
O	1600	1602	an	an	DT	B-NP
O	1603	1611	increase	increase	NN	I-NP
O	1612	1614	in	in	IN	B-PP
O	1615	1624	apoptosis	apoptosis	NN	B-NP
O	1625	1627	of	of	IN	B-PP
O	1628	1634	latent	latent	JJ	B-NP
O	1635	1639	gene	gene	NN	I-NP
O	1639	1640	-	-	HYPH	O
O	1640	1650	expressing	express	VBG	B-VP
B-Cell	1651	1656	cells	cell	NNS	B-NP
O	1657	1662	after	after	IN	B-PP
O	1663	1666	the	the	DT	B-NP
O	1667	1680	pharmacologic	pharmacologic	JJ	I-NP
O	1681	1689	deletion	deletion	NN	I-NP
O	1690	1692	of	of	IN	B-PP
O	1693	1696	the	the	DT	B-NP
O	1697	1702	vGPCR	vGPCR	NN	I-NP
O	1702	1703	-	-	HYPH	O
O	1703	1713	expressing	express	VBG	B-VP
B-Cell	1714	1719	cells	cell	NNS	B-NP
O	1719	1720	.	.	.	O

O	1721	1726	These	These	DT	B-NP
O	1727	1735	findings	finding	NNS	I-NP
O	1736	1744	indicate	indicate	VBP	B-VP
O	1745	1749	that	that	IN	B-SBAR
O	1750	1755	vGPCR	vGPCR	NN	B-NP
O	1756	1759	may	may	MD	B-VP
O	1760	1764	play	play	VB	I-VP
O	1765	1766	a	a	DT	B-NP
O	1767	1770	key	key	JJ	I-NP
O	1771	1775	role	role	NN	I-NP
O	1776	1778	in	in	IN	B-PP
B-Cancer	1779	1785	Kaposi	Kaposi	NNP	B-NP
I-Cancer	1785	1786	'	'	POS	B-NP
I-Cancer	1786	1787	s	s	JJ	I-NP
I-Cancer	1788	1795	sarcoma	sarcoma	NN	I-NP
O	1796	1807	progression	progression	NN	I-NP
O	1808	1811	and	and	CC	O
O	1812	1819	provide	provide	VBP	B-VP
O	1820	1832	experimental	experimental	JJ	B-NP
O	1833	1846	justification	justification	NN	I-NP
O	1847	1850	for	for	IN	B-PP
O	1851	1861	developing	develop	VBG	B-VP
O	1862	1871	molecular	molecular	JJ	B-NP
O	1871	1872	-	-	HYPH	I-NP
O	1872	1877	based	base	VBN	I-NP
O	1878	1887	therapies	therapy	NNS	I-NP
O	1888	1900	specifically	specifically	RB	B-VP
O	1901	1910	targeting	target	VBG	I-VP
O	1911	1916	vGPCR	vGPCR	NN	B-NP
O	1917	1920	and	and	CC	O
O	1921	1924	its	its	PRP$	B-NP
O	1925	1934	effectors	effector	NNS	I-NP
O	1935	1938	for	for	IN	B-PP
O	1939	1942	the	the	DT	B-NP
O	1943	1952	treatment	treatment	NN	I-NP
O	1953	1955	of	of	IN	B-PP
B-Cancer	1956	1962	Kaposi	Kaposi	NNP	B-NP
I-Cancer	1962	1963	'	'	POS	B-NP
I-Cancer	1963	1964	s	s	JJ	I-NP
I-Cancer	1965	1972	sarcoma	sarcoma	NN	I-NP
O	1973	1981	patients	patient	NNS	I-NP
O	1981	1982	.	.	.	O

